OrbusNeich Deepens Collaboration with SonoScape to Expand Exclusive Distribution Rights for IVUS Systems Across APAC and Europe

(Hong Kong, July 21, 2025) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929.HK), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, today announced that it has entered into new exclusive distribution agreements with SonoScape Medical Corp. (“SonoScape”), pursuant to which OrbusNeich will distribute SonoScape’s intravascular ultrasound (“IVUS”) systems in 12 markets across Asia-Pacific (“APAC”) and Europe on exclusive basis, significantly expanding its cardiovascular portfolio and advancing efforts to enhance patient care globally.

Building on the successful collaboration established with SonoScape last December for the sole and exclusive distribution rights of the same products in Hong Kong and Macau, the Group has expanded the long-term strategic partnership to include 6 direct sales markets, including France, Germany, Malaysia, Spain, Singapore and Switzerland and 6 distributor sales markets in Europe. The agreements will enable the Group to diversify its product portfolio and create cross-selling opportunities, delivering innovative cardiovascular solutions to a wider patient community through its well-established global distribution network. In addition, OrbusNeich and SonoScape are engaged in ongoing negotiations to explore potential collaborations in other parts of APAC, aligning with OrbusNeich’s commitment to global growth and improving access to healthcare worldwide.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “We are pleased to deepen our partnership with SonoScape by combining our global commercialization expertise with their cutting-edge IVUS technology to address unmet clinical needs in various parts of the world. By empowering physicians with more precise vascular intervention tools to improve patient outcomes, we are also expanding our global footprint in high-growth markets. We look forward to working closely with SonoScape to deliver more benefits to the international healthcare ecosystems. In the future, we will leverage this proven model to introduce high-impact products into more markets, creating shared value for partners, healthcare providers, and patients worldwide.”

Sonoscape’s V20 and V20P ultra-wideband IVUS systems obtained CE Mark in March 2025. Innovations have been made in image processing by using single-crystal materials in the IVUS catheters, broadening the ultrasound bandwidth to 20-80 MHz, thereby improving penetration and image resolution. The products’ high frame rate and fast pullback speed effectively minimize longitudinal jagged artifacts. Additionally, intelligent features like Long-Axis Smart Analytics enhance stent size selection and landing point determination. The V20P model, in particular, is the world’s smallest IVUS system, offering portability with a high-capacity battery and touchscreen, while the V20 model includes a dual-screen interface for real-time remote diagnosis, multi-device connectivity, and collaborative consultation, making them ideal for dynamic clinical environments.

－ End －

About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.

For more information, please visit the Group’s official website: https://orbusneich.com/.

About SonoScape Medical Corp.
SonoScape Medical Corp. (stock code: 300633.SZ) is a leading innovator of medical technology specializing in ultrasound medical imaging, endoscopic diagnosis and treatment, minimally invasive surgery, and cardiovascular intervention solutions. Offering professional medical solutions and support in over 170 countries, SonoScape is driven by a passion for continuous innovation, unlocking life’s potential and paving the way for boundless advancements in healthcare.

For more information, please visit SonoScape’s official website: https://www.sonoscape.com/.